Glofitamab Effective in Relapsed, Refractory Diffuse Large B-Cell Lymphoma

Glofitamab (Genentech), a T-cell bispecific antibody, is effective for patients with relapsed or refractory diffuse large B-cell lymphoma. In a study of 154 patients, researchers found that 39% had a complete response at a median follow-up of 12.6 months.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ